5610 results
Refine Your Search
Andrew Lane
Dr. Lane’s laboratory and translational research focuses on the biology of blood cancers, including acute myeloid leukemia (AML), myelodysplastic syn…
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): understanding disease biology to improve therapy
We focus on blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive blood cancer with limited treatment options and poor outcomes. We want…
TAP Partner News During SITC: Nov 2021
Current and former TAP partners presented new data during the The Society for Immunotherapy of Cancer (SITC) meeting that took place from November -1…
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at 2021 SITC Annual Meeting
Heidelberg, Germany, October , – Affimed N.V. (Nasdaq: AFMD), a company committed to giving patients back their innate ability to fight cancer, tod…
Kymera Therapeutics Receives IND Clearance for KT-333, a STAT3 Degrader, for the Treatment of Hematologic and Solid Malignancies
WATERTOWN, Mass., Nov. , - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver n…
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR treatment …
FDA Approves the First Interferon for Adults With Polycythemia Vera
This is the first medication approved for PV that patients can take regardless of their treatment history, meaning it can be used to treat this rare f…
News Release
LLS Applauds House Passage of Critical Health Reforms
The Leukemia & Lymphoma Society applauds passage of critical reforms by the U.S. House of Representatives. The provisions, components of the Build Ba…
News Release
Angela
I am a Hodgkin lymphoma (HL) cancer survivor. I was first diagnosed with stage HL in . I underwent chemo and radiation. The doctors at my were no l…
Halley
My story with cancer began long before I was diagnosed this year at . When I was years old, my - sister, Hannah, became too tired to play with me. As…
Dan
My name is Dan. I was first diagnosed with multiple myeloma (MM). After a battery of excruciating, painful biopsies and bloodwork, my doctors prescrib…
Stories
Amina
I’m years old, and I have stage 3B Hodgkin lymphoma (HL).I was years old, living in New York, and in my final semester of conservatory dance trainin…
New Eyes
To provide eyeglasses to individuals in need Provides a basic pair of single or lined bifocal eyeglasses at no cost to individuals who meet the…
Non-Hodgkin Lymphoma: Know Your Subtype
Topics CoveredWe invite you to learn more about:The importance of knowing your lymphoma (NHL) subtypeHow your NHL subtype guides your treatment goals…
Education Resources
Hair We Share
To help maintain dignity, confidence and to those affected by medical hair loss. Provides a wig free of charge to children years old and under…
FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse
The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectabl…
News Release
Gary
In I had a lump on my neck, and after strong urging from my wife and my mother, I finally went to my family doctor. My white blood cell counts were r…
Elephants and Tea
To help adolescent and young adult (AYA) patients, survivors, and caregivers know they are not alone in their fight with cancer Provides a free …
TAP Partner News During ASH: Dec 2021
Current and former TAP partners presented new data during the American Society of Hematology (ASH) meeting that took place from December -14th.
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
December - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced data from the pivotal trial of Yescarta® (axicabtagene c…
Secura Bio Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory PTCL
SUMMERLIN, Nev., Dec. , - Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impa…
Blood Cancers: Managing Side Effects
Topics Covered We invite you to learn more about: Typical side effects of different drug classes How your treatment team can treat your side effe…